Skip to main content

Table 1 Baseline Demographics

From: Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial

  All Groups Placebo Treatment P-value
Age (years) 67 ± 14 65 ± 16 67 ± 11 0.53
Gender (n, % Female) 13/40 (33%) 6/20 (30%) 7/20 (35%) 0.74
Race (n, % Caucasian) 38/40 (95%) 19/20 (95%) 19/20(95%) 1
BMI (kg/m2−) 29 ± 5 28 ± 5 31 ± 5 0.33
HR (BPM) 72 ± 11 70 ± 10 74 ± 11 0.92
Systolic BP (mmHg) 113 ± 16 117 ± 19 110 ± 14 0.38
Diastolic BP (mmHg) 69 ± 10 71 ± 10 67 ± 10 0.42
EF (%) 28 ± 9 30 ± 11 27 ± 7 0.13
Ischemic (#, %) 25/40 (63%) 14/20 (70%) 11/20 (55%) 0.33
Nonischemic (#, %) 15/40 (37%) 6/20(30%) 9/20 (45%) 0.33
ACE/ARB (#, %) 33/40 (83%) 17/20 (85%) 16/20 (80%) 0.68
Digoxin (#, %) 4/40 (10%) 2/20 (10%) 2/20 (10%) 1
Beta Blocker (#, %) 32/40 (80%) 14/20 (70%) 18/20 (90%) 0.11
Loop Diuretic (#, %) 28/40 (70%) 13/20 (65%) 15/20 (75%) 0.49
Spironolactone and/or Eplerenone 31/40 (78%) 16/20 (80%) 15/20 (75%) 0.70
Statins (#, %) 29/40 (73%) 15/20 (75%) 14/20 (70%) 0.72
  1. Data are expressed as mean ± standard deviation (SD) or number and percentages. Abbreviations: Body Mass Index (BMI), Heart Rate (HR), Blood Pressure (BP), Ejection Fraction (EF) Angiotensin Converting Enzyme Inhibitor (ACE), Angiotensin Receptor Blocker (ARB)